Primary Angiosarcoma of the Ovary: A Case Report and Literature Review

In: Case Reports in Oncology · 2026 · pp. 1–19 · doi:10.1159/000551775 · W7140971741
article OA: gold CC0

Abstract

Introduction: Primary angiosarcoma of the ovary is an exceptionally rare and aggressive malignancy, representing a diagnostic and therapeutic challenge. Due to its rarity, standardized management protocols are lacking, and prognosis remains poor. Case Presentation: A 45-year-old woman with diabetes and hypertension presented with abdominal pain and a palpable pelvic mass. Imaging revealed a complex right adnexal mass. She underwent total abdominal hysterectomy with bilateral salpingo-oophorectomy. Histopathological examination revealed a high-grade pleomorphic tumor. Immunohistochemistry was pivotal for diagnosis, showing strong positivity for CD31 and ERG, and negativity for epithelial markers, confirming a primary pure ovarian angiosarcoma (FIGO Stage II). Postoperative PET-CT showed no distant metastasis. Following a multidisciplinary tumor board review, she received four cycles of adjuvant carboplatin and paclitaxel. At six-month follow-up, she remained asymptomatic with no evidence of recurrence. Conclusion: This case underscores the importance of a comprehensive immunohistochemical panel in diagnosing rare ovarian malignancies, particularly to distinguish angiosarcoma from other poorly differentiated tumors. Multidisciplinary management is essential. While adjuvant chemotherapy may offer benefit, the prognosis for advanced-stage ovarian angiosarcoma remains guarded. This report adds to the limited literature on this entity and highlights the need for further research to establish optimal treatment strategies.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

openalex
last seen: 2026-05-13T19:41:59.147868+00:00
License: CC0 · commercial use OK